ES3005507T3 - Combination therapy for treating cancer - Google Patents

Combination therapy for treating cancer Download PDF

Info

Publication number
ES3005507T3
ES3005507T3 ES21794474T ES21794474T ES3005507T3 ES 3005507 T3 ES3005507 T3 ES 3005507T3 ES 21794474 T ES21794474 T ES 21794474T ES 21794474 T ES21794474 T ES 21794474T ES 3005507 T3 ES3005507 T3 ES 3005507T3
Authority
ES
Spain
Prior art keywords
cancer
azd5305
pharmaceutically acceptable
acceptable salt
carboplatin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES21794474T
Other languages
English (en)
Spanish (es)
Inventor
Elisabetta Leo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Application granted granted Critical
Publication of ES3005507T3 publication Critical patent/ES3005507T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ES21794474T 2020-10-08 2021-10-07 Combination therapy for treating cancer Active ES3005507T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063089195P 2020-10-08 2020-10-08
PCT/EP2021/077703 WO2022074124A1 (en) 2020-10-08 2021-10-07 Combination therapy for treating cancer

Publications (1)

Publication Number Publication Date
ES3005507T3 true ES3005507T3 (en) 2025-03-14

Family

ID=78293953

Family Applications (1)

Application Number Title Priority Date Filing Date
ES21794474T Active ES3005507T3 (en) 2020-10-08 2021-10-07 Combination therapy for treating cancer

Country Status (19)

Country Link
US (1) US20230372333A1 (cg-RX-API-DMAC7.html)
EP (1) EP4225297B1 (cg-RX-API-DMAC7.html)
JP (1) JP7818585B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230083291A (cg-RX-API-DMAC7.html)
CN (1) CN116194110B (cg-RX-API-DMAC7.html)
AU (1) AU2021356123B2 (cg-RX-API-DMAC7.html)
BR (1) BR112023005160A2 (cg-RX-API-DMAC7.html)
CA (1) CA3197056A1 (cg-RX-API-DMAC7.html)
DK (1) DK4225297T3 (cg-RX-API-DMAC7.html)
ES (1) ES3005507T3 (cg-RX-API-DMAC7.html)
FI (1) FI4225297T3 (cg-RX-API-DMAC7.html)
HU (1) HUE069249T2 (cg-RX-API-DMAC7.html)
IL (1) IL301687A (cg-RX-API-DMAC7.html)
MX (1) MX2023004156A (cg-RX-API-DMAC7.html)
PL (1) PL4225297T3 (cg-RX-API-DMAC7.html)
PT (1) PT4225297T (cg-RX-API-DMAC7.html)
TW (1) TW202228693A (cg-RX-API-DMAC7.html)
WO (1) WO2022074124A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202304965B (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202304911A (zh) * 2021-04-23 2023-02-01 大陸商南京明德新藥研發有限公司 吡啶醯胺類化合物
WO2023036285A1 (zh) * 2021-09-09 2023-03-16 南京奥利墨斯医药科技有限公司 一种杂芳环类化合物及其应用
US20230250428A1 (en) * 2022-02-07 2023-08-10 Alliance Of Cardiovascular Researchers Method and composition for early detection of malignancies
IL316019A (en) * 2022-04-07 2024-11-01 Astrazeneca Ab Combined treatment for cancer
CA3254948A1 (en) * 2022-04-07 2023-10-12 Astrazeneca Ab Polytherapy for the treatment of cancer
CN121464135A (zh) * 2023-07-07 2026-02-03 优领医药科技(香港)有限公司 含哌嗪并环类衍生物的晶型、其盐型、其制备方法及应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6648040B2 (ja) * 2014-05-28 2020-02-14 エーザイ・アール・アンド・ディー・マネジメント株式会社 がん治療のための併用療法としてのエリブリン及びポリ(adpリボース)ポリメラーゼ(parp)阻害剤の使用
TWI837403B (zh) * 2019-07-19 2024-04-01 瑞典商阿斯特捷利康公司 化學化合物

Also Published As

Publication number Publication date
HUE069249T2 (hu) 2025-02-28
DK4225297T3 (da) 2025-01-02
KR20230083291A (ko) 2023-06-09
PT4225297T (pt) 2024-12-30
EP4225297A1 (en) 2023-08-16
JP2023546362A (ja) 2023-11-02
FI4225297T3 (fi) 2024-12-10
US20230372333A1 (en) 2023-11-23
WO2022074124A1 (en) 2022-04-14
AU2021356123B2 (en) 2025-01-09
CA3197056A1 (en) 2022-04-14
EP4225297B1 (en) 2024-10-23
ZA202304965B (en) 2024-09-25
TW202228693A (zh) 2022-08-01
CN116194110B (zh) 2025-06-17
PL4225297T3 (pl) 2025-03-17
CN116194110A (zh) 2023-05-30
MX2023004156A (es) 2023-05-03
IL301687A (en) 2023-05-01
AU2021356123A1 (en) 2023-06-08
BR112023005160A2 (pt) 2023-04-18
JP7818585B2 (ja) 2026-02-20

Similar Documents

Publication Publication Date Title
AU2021356123B2 (en) Combination therapy for treating cancer
ES2818620T3 (es) Derivados de azabencimidazol como inhibidores de pi3k beta
ES3036500T3 (en) Pyrazine derivative as chk1 inhibitor
ES2504690T3 (es) Compuestos inhibidores de PARP, composiciones y métodos de uso
ES2928169T3 (es) Derivados de 4-(3H-indol-5-il)-N-(piridin-2-il)pirimidin-2-amina como inhibidores de proteína cinasa, y método de preparación y uso médico de los mismos
ES2895365T3 (es) Pirimidopirimidinonas útiles como inhibidores de la quinasa Wee-1
US11666574B2 (en) Combination therapy involving diaryl macrocyclic compounds
JP2008509948A5 (cg-RX-API-DMAC7.html)
JP2023545096A (ja) 抗体-薬物コンジュゲート及びparp1選択的阻害薬の組み合わせ
TW202131930A (zh) 抗癌核荷爾蒙受體標靶化合物
CN102824346B (zh) 使用10-炔丙基-10-去氮杂氨基蝶呤治疗t细胞淋巴瘤
AU2007264665B2 (en) Potentiator of radiation therapy
CN115677824B (zh) 可诱导sos1蛋白质降解的化合物、制备方法和用途
EP3125901B1 (en) Derivatives of cephalosporin for treating cancer
CN106459011B (zh) 作为抗肿瘤化合物的σ-2受体配体药物缀合物、其合成方法及其用途
ES2760507T3 (es) Derivados de imidazopiridazina enlazados a heterociclilo como inhibidores de PI3Kß
CN111643502A (zh) 喹啉衍生物联合化疗药物用于治疗非小细胞肺癌
EA049465B1 (ru) Комбинированная терапия для лечения рака
HK40099137B (en) Combination therapy for treating cancer
HK40099137A (en) Combination therapy for treating cancer
US20180296579A1 (en) Methods of treating ibrutinib-resistant disease
CN114502179A (zh) 含锰配合物的水性制剂的制备方法、制剂和治疗方法
CN120904168A (zh) 第四代egfr抑制剂、及其制备方法和在药学上的应用
BR122024006404A2 (pt) Compostos inibidores de tirosina e de cdc2 específica de treonina cinase e composição farmacêutica compreendendo os mesmos
WO2025063888A1 (en) Survivin-targeted compounds